

NOVAVAX INC  
Form 8-K  
May 05, 2004

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO 13 or 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): May 5, 2004

**NOVAVAX, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation or organization)

**0-26770**

(Commission  
File No.)

**22-2816046**

(I.R.S. Employer  
Identification No.)

**8320 Guilford Road, Columbia, MD**

(Address of principal executive offices)

**21046**

(Zip code)

**(301) 854-3900**

Registrant's telephone number, including area code

**Not applicable**

(Former name or former address, if changed since last report)

---

**NOVAVAX, INC.**  
**ITEMS TO BE INCLUDED IN THIS REPORT**

**ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.**

99.1 Press Release dated May 5, 2004.

**ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.**

On May 5, 2004, Novavax, Inc. reported its first quarter earnings for 2004.

A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 5, 2004      By: NOVAVAX, INC.  
/s/ Dennis W. Genge  
Dennis W. Genge  
Vice President and Chief Financial Officer